Chen et al. [23] investigated the expression of CD155 and PD-L1 in triple-negative breast cancer cell lines, and showed that activation of the CD155 pathway caused resistance to anti-PD-L1 treatment. This evidence concerns the gene PVR and triple-negative breast carcinoma.